Aprea Therapeutics, Inc. financial data

Symbol
APRE on Nasdaq
Location
3805 Old Easton Road, Doylestown, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 758 % -6.18%
Debt-to-equity 15.1 % -45.9%
Return On Equity -56.4 % -2.08%
Return On Assets -46.3 % -2.25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.43M shares +45.4%
Common Stock, Shares, Outstanding 5.43M shares +45.5%
Entity Public Float 10M USD -28.6%
Common Stock, Value, Issued 5.43K USD +45.5%
Weighted Average Number of Shares Outstanding, Basic 5.94M shares +59.1%
Weighted Average Number of Shares Outstanding, Diluted 5.94M shares +59.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.2M USD -40.3%
General and Administrative Expense 7.14M USD +11.4%
Operating Income (Loss) -14.2M USD -5.35%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -12.9M USD +8.35%
Earnings Per Share, Basic -2.99 USD/shares -113%
Earnings Per Share, Diluted -2.99 USD/shares -113%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.7M USD +3.65%
Assets, Current 29.6M USD +3.22%
Property, Plant and Equipment, Net 92.4K USD +5376%
Operating Lease, Right-of-Use Asset 107K USD -57.2%
Other Assets, Noncurrent 271K USD
Assets 30M USD +4.48%
Accounts Payable, Current 964K USD -14.8%
Employee-related Liabilities, Current 582K USD -54.3%
Liabilities, Current 3.09M USD -21.7%
Operating Lease, Liability, Noncurrent 28.1K USD -16.9%
Liabilities 3.95M USD -48.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10.6M USD +0.06%
Retained Earnings (Accumulated Deficit) -314M USD -4.29%
Stockholders' Equity Attributable to Parent 25.6M USD +9.14%
Liabilities and Equity 30M USD +4.48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.94M USD -32.1%
Net Cash Provided by (Used in) Financing Activities 14.7M USD +186%
Net Cash Provided by (Used in) Investing Activities -7.98K USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 5.43M shares +45.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.7M USD +3.65%
Deferred Tax Assets, Valuation Allowance 49.4M USD +13.3%
Deferred Tax Assets, Gross 49.4M USD +13.3%
Operating Lease, Liability 111K USD -56.4%
Payments to Acquire Property, Plant, and Equipment 7.98K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.9M USD +10.7%
Lessee, Operating Lease, Liability, to be Paid 112K USD -57.2%
Property, Plant and Equipment, Gross 138K USD +205%
Operating Lease, Liability, Current 111K USD -50.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 53.2K USD -72.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.42K USD -82.1%
Deferred Tax Assets, Operating Loss Carryforwards 41.8M USD +7.58%
Preferred Stock, Shares Authorized 40M shares 0%
Operating Lease, Payments 246K USD -3.72%
Additional Paid in Capital 351M USD +4.49%
Depreciation, Depletion and Amortization 6.16K USD +1402%
Share-based Payment Arrangement, Expense 128K USD -52.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%